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The recent announcement that a Lasker award has been attributed to Professor Alim-Louis Benabid
for pioneering the application of high frequency stimulation, named deep brain stimulation, of the
subthalamic nucleus in patients suffering from Parkinson’s disease prompts us to evoke the decisive
role played by the non-human primate model in the discovery of this neurosurgical therapy, now
regarded as the current therapeutic gold standard of the disease.
The era of human functional surgery started in the 1950s by performing ablative procedures
aiming to avoid the side effects of the commonly performed frontal lobotomy in the treatment of
psychiatric illness (Spiegel et al., 1952). During surgery, intraoperative electrical stimulation was
used from the beginning to explore the brain target prior to ablation. During the same period of
time, Delgado et al. (1952) were the first to develop a technique of subcortical stimulation using
chronically implanted electrodes connected to a subcutaneous receiver implanted in the scalp, a
“Stimoceiver,” that could be controlled by radio waves. This technique of “radio communication
with the brain” was initially developed for use in psychiatric patients. The chronological order of
applications of chronic deep brain stimulation was first for psychiatry and behavior, then for pain
and epilepsy. Deep brain stimulation for Parkinson’s disease and other movement disorders was
the last indication of the older era of chronic subcortical stimulation. Hariz and colleagues reported
a detailed history of deep brain stimulation between 1947 and 1987 (Hariz et al., 2010).
In the late 1980s, considerable progress was made in the understanding of the role played
by the basal ganglia in the pathophysiology of Parkinson’s disease (Albin et al., 1989) and the
subthalamic nucleus was highlighted as an optimal therapeutic target. This small nucleus, the only
excitatory glutamatergic structure of the basal ganglia network (Smith and Parent, 1988) playing a
key role in movement control (DeLong, 1990), is considered as a driving force regulating the basal
ganglia output nuclei; it was therefore suggested that activation of the subthalamic nucleus should
inhibit movement and conversely its inhibition should be related to the release of movement. Back
in 1927 it had already been reported that a focal lesion of the subthalamic area could induce
hemiballismus, the manifestation of abnormal involuntary movements (Martin, 1927) and this
association was reproduced later by lesion of the subthalamic nucleus in the non-human primate
(Hammond et al., 1979). Single unit extracellular electrophysiology (Miller and De Long, 1987) and
autoradiography of 2-deoxyglucose uptake (Mitchell et al., 1989) likewise showed that systemic
injection of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
resulted in dopamine cell degeneration in the substantia nigra pars compacta and the manifestation
of akinesia and rigidity, associated with a hyperactivity of subthalamic nucleus neurons.
In the light of these results, Bergman et al. (1990) and Aziz et al. (1991) a year later proposed
therapeutic lesion of the subthalamic nucleus and both demonstrated an effective alleviation of
parkinsonian motor symptoms in monkeys. Since lesioned animals unfortunately also developed
severely abnormal involuntary movements, this irreversible approach could not be proposed to
patients.
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Pursuing a parallel line of research, our team in Bordeaux
at the “Centre National de la Recherche Scientifique” (CNRS)
was the first, in the period 1991-1992, to carry out rigorous
studies of the effects of high frequency stimulation of the
subthalamic nucleus in Macaca mulatta monkeys rendered
parkinsonian by MPTP, observations which allowed objective
quantification of the modifications of the principal movement
parameters this treatment induced. The results obtained were
spectacular; rigidity disappeared and akinesia was hardly
observable (Benazzouz et al., 1993).
Impressed by these results, we proposed the transfer of
this neurosurgical approach to parkinsonian patients. Only a
few months later, in collaboration with our team, Alim-Louis
Benabid who was already a recognized expert in the field
of functional neurosurgery and who realized the importance
of these observations, attempted the first application of high
frequency stimulation of the subthalamic nucleus in human
patients (Pollak et al., 1993; Limousin et al., 1995) with a success
that has never failed since.
This example of cooperation provides a perfect illustration of
how irreplaceable the phylogenetic proximity between humans
and non-human primates can be, not only from the physiological
and clinical point of view but also for the design of relevant
pathophysiological models and the definition of new therapeutic
strategies.
In such an exemplary case of ≪ bench to bedside ≫
translation, it is important to cite all the links that have built the
chain and engendered such positive results.
This is a new era of neuromodulation and it is clear
now that the success of this functional neurosurgery involves
the modulation of circuitry properties and cortical-subcortical
synchronies involving also stations not strictly attributable
to the direct/indirect pathway scheme (Stefani et al., 2007).
Furthermore, despite possible adverse events, deep brain
stimulation in patients contributed in large part to the
understanding of the pathophysiology of Parkinson’s disease
and opened the way to the treatment of a number of chronic
and disabling neurologic and psychiatric disorders. In order to
ensure continued progress in this field, we need to have a better
understanding of the pathophysiology of brain diseases, as well as
to develop a next generation of electrodes and stimulation devices
with combined electrical and chemical sensing (Rosin et al., 2011;
Priori et al., 2013). These technological improvements cannot be
done without complimentary works in patients and laboratoty
animal models of brain diseases.
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